peroxisome biogenesis disorder 10A (Zellweger)
disease diseaseOn this page
Also known as PBD10A
Summary
peroxisome biogenesis disorder 10A (Zellweger) (MONDO:0013948) is a disease caused by PEX3 (GenCC Definitive), with 1 cohort gene.
At a glance
- Causal gene: PEX3 (GenCC Definitive)
- Cohort genes: 1
- ClinVar variants: 60
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | peroxisome biogenesis disorder 10A (Zellweger) |
| Mondo ID | MONDO:0013948 |
| OMIM | 614882 |
| DOID | DOID:0080484 |
| UMLS | C3553999 |
| MedGen | 766913 |
| GARD | 0015873 |
| Is cancer (heuristic) | no |
Also known as: PBD10A · peroxisome biogenesis disorder 10A (Zellweger)
Data availability: 60 ClinVar variants · 3 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by developmental or physiological process › metabolic disease › developmental anomaly of metabolic origin › Zellweger spectrum disorders › peroxisome biogenesis disorder due to PEX3 defect › peroxisome biogenesis disorder 10A (Zellweger)
Related subtypes (1): peroxisome biogenesis disorder 10B
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
60 retrieved; paginated sample, class counts are floors:
32 uncertain significance, 8 conflicting classifications of pathogenicity, 6 benign, 4 likely pathogenic, 3 benign/likely benign, 3 likely benign, 2 pathogenic/likely pathogenic, 2 pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 597138 | NM_003630.3(PEX3):c.288-1G>A | PEX3 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 631556 | NM_003630.3(PEX3):c.942-8T>G | PEX3 | Pathogenic | criteria provided, single submitter |
| 6618 | NM_003630.3(PEX3):c.543dup (p.Val182fs) | PEX3 | Pathogenic | no assertion criteria provided |
| 973435 | NM_003630.3(PEX3):c.292_302del (p.Ser98fs) | PEX3 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1065621 | NM_003630.3(PEX3):c.844A>C (p.Thr282Pro) | PEX3 | Likely pathogenic | criteria provided, single submitter |
| 2627431 | NM_003630.3(PEX3):c.144C>A (p.Tyr48Ter) | PEX3 | Likely pathogenic | criteria provided, single submitter |
| 3065043 | NM_003630.3(PEX3):c.74G>T (p.Gly25Val) | PEX3 | Likely pathogenic | criteria provided, single submitter |
| 3593211 | NM_003630.3(PEX3):c.-4_12del (p.Met1fs) | PEX3 | Likely pathogenic | criteria provided, single submitter |
| 195197 | NM_003630.3(PEX3):c.165A>G (p.Gln55=) | PEX3 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 289544 | NM_003630.3(PEX3):c.578+8A>G | PEX3 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 291279 | NM_003630.3(PEX3):c.473C>G (p.Pro158Arg) | PEX3 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 355573 | NM_003630.3(PEX3):c.51C>T (p.Ile17=) | PEX3 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 355574 | NM_003630.3(PEX3):c.96T>C (p.Tyr32=) | PEX3 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 355576 | NM_003630.3(PEX3):c.249A>G (p.Gln83=) | PEX3 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 355579 | NM_003630.3(PEX3):c.*220G>A | PEX3 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 906787 | NM_003630.3(PEX3):c.332-9T>A | PEX3 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1029734 | NM_003630.3(PEX3):c.1048A>C (p.Thr350Pro) | PEX3 | Uncertain significance | criteria provided, single submitter |
| 1366095 | NM_003630.3(PEX3):c.553C>A (p.Gln185Lys) | PEX3 | Uncertain significance | criteria provided, single submitter |
| 355568 | NM_003630.3(PEX3):c.-214G>C | PEX3 | Uncertain significance | criteria provided, single submitter |
| 355571 | NM_003630.3(PEX3):c.-175G>C | PEX3 | Uncertain significance | criteria provided, single submitter |
| 355577 | NM_003630.3(PEX3):c.887C>T (p.Ala296Val) | PEX3 | Uncertain significance | criteria provided, single submitter |
| 355578 | NM_003630.3(PEX3):c.*129C>T | PEX3 | Uncertain significance | criteria provided, single submitter |
| 355584 | NM_003630.3(PEX3):c.*424T>C | PEX3 | Uncertain significance | criteria provided, single submitter |
| 355586 | NM_003630.3(PEX3):c.*573A>G | PEX3 | Uncertain significance | criteria provided, single submitter |
| 355587 | NM_003630.3(PEX3):c.*677C>T | PEX3 | Uncertain significance | criteria provided, single submitter |
| 355588 | NM_003630.3(PEX3):c.*793T>C | PEX3 | Uncertain significance | criteria provided, single submitter |
| 355590 | NM_003630.3(PEX3):c.*958T>C | PEX3 | Uncertain significance | criteria provided, single submitter |
| 355591 | NM_003630.3(PEX3):c.*1074A>G | PEX3 | Uncertain significance | criteria provided, single submitter |
| 355592 | NM_003630.3(PEX3):c.*1305C>T | PEX3 | Uncertain significance | criteria provided, single submitter |
| 355593 | NM_003630.3(PEX3):c.*1332A>G | PEX3 | Uncertain significance | criteria provided, single submitter |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 6 · Orphanet: 3 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| PEX3 | Definitive | Autosomal recessive | peroxisome biogenesis disorder 10A (Zellweger) | 6 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| PEX3 | Orphanet:44 | Neonatal adrenoleukodystrophy |
| PEX3 | Orphanet:772 | Infantile Refsum disease |
| PEX3 | Orphanet:912 | Zellweger syndrome |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| PEX3 | HGNC:8858 | ENSG00000034693 | P56589 | Peroxisomal biogenesis factor 3 | gencc,clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| PEX3 | Peroxisomal biogenesis factor 3 | Involved in peroxisome biosynthesis and integrity. |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 1 | 1.8× | 0.558 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| PEX3 | Other/Unknown | no | Peroxin-3 |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| adrenal tissue | 1 |
| endothelial cell | 1 |
| right adrenal gland cortex | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| PEX3 | 291 | ubiquitous | marker | adrenal tissue, endothelial cell, right adrenal gland cortex |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| PEX3 | 1,838 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| PEX3 | P56589 | 2 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 2. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| ABC transporters in lipid homeostasis | 1 | 601.0× | 0.002 | PEX3 |
| Class I peroxisomal membrane protein import | 1 | 519.1× | 0.002 | PEX3 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| protein import into peroxisome membrane | 1 | 2808.7× | 7e-04 | PEX3 |
| peroxisome organization | 1 | 802.5× | 0.001 | PEX3 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| PEX3 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| PEX3 | 1 | Binding:1 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 1 | PEX3 |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| PEX3 | 1 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: PEX3